WO1998041648A3 - Target genes for allele-specific drugs - Google Patents
Target genes for allele-specific drugs Download PDFInfo
- Publication number
- WO1998041648A3 WO1998041648A3 PCT/US1998/005419 US9805419W WO9841648A3 WO 1998041648 A3 WO1998041648 A3 WO 1998041648A3 US 9805419 W US9805419 W US 9805419W WO 9841648 A3 WO9841648 A3 WO 9841648A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- allele
- target genes
- genes
- loh
- loss
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98912974A EP0973935A2 (en) | 1997-03-20 | 1998-03-19 | Target genes for allele-specific drugs |
AU67643/98A AU6764398A (en) | 1997-03-20 | 1998-03-19 | Target genes for allele-specific drugs |
CA002283636A CA2283636A1 (en) | 1997-03-20 | 1998-03-19 | Target genes for allele-specific drugs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4105797P | 1997-03-20 | 1997-03-20 | |
US60/041,057 | 1997-03-20 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1998041648A2 WO1998041648A2 (en) | 1998-09-24 |
WO1998041648A9 WO1998041648A9 (en) | 1999-01-07 |
WO1998041648A3 true WO1998041648A3 (en) | 1999-04-29 |
Family
ID=21914484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/005419 WO1998041648A2 (en) | 1997-03-20 | 1998-03-19 | Target genes for allele-specific drugs |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0973935A2 (en) |
AU (1) | AU6764398A (en) |
CA (1) | CA2283636A1 (en) |
WO (1) | WO1998041648A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9308204B2 (en) | 2009-11-02 | 2016-04-12 | Pfizer Inc. | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7074902B1 (en) | 1998-04-27 | 2006-07-11 | Warf Wisconsin Alumni Research Foundation | Antibody specific for a DNA repair protein |
US7122343B1 (en) * | 1998-04-27 | 2006-10-17 | Wisconsin Alumni Research Foundation | Methods to alter levels of a DNA repair protein |
GB9828840D0 (en) * | 1998-12-30 | 1999-02-17 | Univ Nottingham Trent | Prostate cancer associated genes and their products |
AU7701100A (en) * | 1999-09-03 | 2001-04-10 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer |
US6309882B1 (en) | 1999-09-10 | 2001-10-30 | Isis Pharmaceuticals, Inc. | Antisense inhibition of replication protein a p70 subunit |
DE60039895D1 (en) * | 1999-09-14 | 2008-09-25 | Scripps Research Inst | NE FOR WHICH YOU CODE |
CA2390051A1 (en) * | 1999-11-15 | 2001-05-25 | University Of Southern California | Thymidylate synthase polymorphism for predicting chemotherapeutic response |
AU1939601A (en) * | 1999-12-01 | 2001-06-12 | Ludwig Institute For Cancer Research | Cancer associated antigens and uses therefor |
US20030092601A1 (en) * | 1999-12-07 | 2003-05-15 | Hanan Polansky | Microcompetition and human disease |
GB0000995D0 (en) * | 2000-01-18 | 2000-03-08 | Zeneca Ltd | Methods |
WO2002021134A2 (en) * | 2000-09-08 | 2002-03-14 | Eos Biotechnology, Inc. | Methods of diagnosing breast cancer and screening for modulators |
US6602670B2 (en) | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
US7049059B2 (en) | 2000-12-01 | 2006-05-23 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression |
US20020142328A1 (en) | 2000-12-01 | 2002-10-03 | Danenberg Kathleen D. | Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors |
US7005278B2 (en) | 2001-03-02 | 2006-02-28 | Danenberg Kathleen D | Method of determining dihydropyrimidine dehydrogenase gene expression |
US6956111B2 (en) | 2001-03-02 | 2005-10-18 | Response Genetics, Inc. | Method of determining dihydropyrimidine dehydrogenase gene expression |
US6686155B2 (en) | 2001-06-14 | 2004-02-03 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
NZ544588A (en) | 2003-06-20 | 2010-06-25 | Nereus Pharmaceuticals Inc | Use of salinosporamide A and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
ES2384940T3 (en) | 2004-01-16 | 2012-07-16 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Immunokinase |
EP1800695A1 (en) * | 2005-12-21 | 2007-06-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Immuno-RNA-constructs |
ES2340206T3 (en) | 2005-12-30 | 2010-05-31 | Ventana Medical Systems, Inc. | EXPRESSION OF NA + K + -ATPASA IN DISPLASTIA AND CANCER CERVICALES. |
US7704967B2 (en) | 2006-03-14 | 2010-04-27 | University Of Maryland, Baltimore | TFIIS and GDOWN1 as targets for cancer therapy |
US8445200B2 (en) | 2009-04-15 | 2013-05-21 | The Regents Of The University Of California | Genotoxicity as a biomarker for inflammation |
HUE045359T2 (en) * | 2011-12-14 | 2019-12-30 | Univ Texas | Collateral gene inactivation biomarkers and targets for cancer therapy |
WO2013174859A1 (en) * | 2012-05-22 | 2013-11-28 | Centre Leon Berard | Screening methods for identifying compounds which interfere with coup-tfii (nr2f2) or coup-tfi (nr2f1) |
US9828641B2 (en) | 2013-08-01 | 2017-11-28 | The Regents Of The University Of California | Systemic genotoxicity as blood marker for allergic inflammation |
WO2015109258A1 (en) * | 2014-01-16 | 2015-07-23 | Rowan University | Modulation of cellular localization of cyclin c |
GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
US20210047696A1 (en) * | 2018-03-28 | 2021-02-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994011494A1 (en) * | 1992-11-09 | 1994-05-26 | Thomas Jefferson University | Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen |
WO1995003335A1 (en) * | 1993-07-26 | 1995-02-02 | K.O. Technology, Inc. | Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents |
US5491064A (en) * | 1992-07-17 | 1996-02-13 | The United States Of America As Represented By The Department Of Health And Human Services | HTS-1 gene, a human tumor suppressor gene |
WO1997004087A1 (en) * | 1995-07-18 | 1997-02-06 | Guido Krupp | Ribozymes for the selective inhibition of expression by mhc allele genes, and drugs containing such ribozymes |
WO1997032024A1 (en) * | 1996-03-01 | 1997-09-04 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Allele suppression |
-
1998
- 1998-03-19 AU AU67643/98A patent/AU6764398A/en not_active Abandoned
- 1998-03-19 WO PCT/US1998/005419 patent/WO1998041648A2/en not_active Application Discontinuation
- 1998-03-19 EP EP98912974A patent/EP0973935A2/en not_active Withdrawn
- 1998-03-19 CA CA002283636A patent/CA2283636A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5491064A (en) * | 1992-07-17 | 1996-02-13 | The United States Of America As Represented By The Department Of Health And Human Services | HTS-1 gene, a human tumor suppressor gene |
WO1994011494A1 (en) * | 1992-11-09 | 1994-05-26 | Thomas Jefferson University | Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen |
WO1995003335A1 (en) * | 1993-07-26 | 1995-02-02 | K.O. Technology, Inc. | Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents |
WO1997004087A1 (en) * | 1995-07-18 | 1997-02-06 | Guido Krupp | Ribozymes for the selective inhibition of expression by mhc allele genes, and drugs containing such ribozymes |
WO1997032024A1 (en) * | 1996-03-01 | 1997-09-04 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Allele suppression |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9308204B2 (en) | 2009-11-02 | 2016-04-12 | Pfizer Inc. | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
US9439902B2 (en) | 2009-11-02 | 2016-09-13 | Pfizer Inc. | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
US9439901B2 (en) | 2009-11-02 | 2016-09-13 | Pfizer Inc. | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Also Published As
Publication number | Publication date |
---|---|
WO1998041648A2 (en) | 1998-09-24 |
CA2283636A1 (en) | 1998-09-24 |
AU6764398A (en) | 1998-10-12 |
EP0973935A2 (en) | 2000-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998041648A3 (en) | Target genes for allele-specific drugs | |
Petryk et al. | Staying true to yourself: mechanisms of DNA methylation maintenance in mammals | |
Worland et al. | Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae | |
Jungmann et al. | Resistance to cadmium mediated by ubiquitin-dependent proteolysis | |
WO1999035170A8 (en) | Compositions and methods for the treatment of tumor | |
WO1999014327A3 (en) | Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer | |
Kaneda et al. | Decreased expression of the seven ARP2/3 complex genes in human gastric cancers | |
US20220307012A1 (en) | Endonuclease-barcoding | |
WO2001009189A3 (en) | Compositions and methods for the treatment of tumors | |
O'connor | An alkaline deoxyribonuclease from rat liver non-histone chromatin proteins | |
WO1994012881A3 (en) | A method for detecting growing cells using translationally controlled tumor protein p21 | |
WO2003008578A3 (en) | Reagents and methods for identifying gene targets for treating cancer | |
WO2004009112A8 (en) | Use of urease for inhibiting cancer cell growth | |
WO2001019966A3 (en) | Isolation of muscle-derived stem cells and uses therefor | |
WO2000015666A3 (en) | Compositions and methods for the treatment of tumors | |
AU4705199A (en) | Differentially expressed genes in pancreatic cancer and displasia | |
Abe et al. | Localization of an hTERT repressor region on human chromosome 3p21. 3 using chromosome engineering | |
Ikehata et al. | Distribution of spontaneous CpG‐associated G: C→ A: T mutations in the lacZ gene of Muta™ mice: Effects of CpG methylation, the sequence context of CpG sites, and severity of mutations on the activity of the lacZ gene product | |
WO2000008157A3 (en) | Human anion transporter genes atnov | |
WO2005033139A3 (en) | Novel calcium channels and uses thereof | |
EP0859059A3 (en) | Methods and materials for introducing exogenous genes into cultured cells or fertilized eggs | |
Lei et al. | Zinc-α2-glycoprotein has ribonuclease activity | |
AU1935399A (en) | Nucleotide and protein sequence of mammastatin and methods of use | |
AU4255899A (en) | Method for non-radioactive detection of membrane-bonded nucleic acids and test kit | |
AU2311697A (en) | Immuno-magnetic cell separation used in identification of genes associated with site-preferenced cancer methastasis formation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1-333, DESCRIPTION, REPLACED BY NEW PAGES 1-333; PAGES 334-389, CLAIMS, REPLACED BY NEW PAGES334-389; PAGES 1/214-214/214, DRAWINGS, REPLACED BY NEW PAGES 1/249-249/249; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2283636 Country of ref document: CA Ref country code: CA Ref document number: 2283636 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 67643/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998912974 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998912974 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998540801 Format of ref document f/p: F |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998912974 Country of ref document: EP |